You searched for "disease"
Infections and inflammation: Part 1
See also Part 2 and Part 3. Case 1 A 59-year-old man presented with right loin pain. His GP arranged for him to have an intravenous urogram (IVU) and subsequent CT urogram performed. What is the likely diagnosis? What are...Use of MRI in the evaluation of prostate cancer: part 1
Introduction Prostate cancer remains the most commonly diagnosed cancer in males and the second leading cause of cancer related deaths in UK men, after lung cancer [1]. The incidence of prostate cancer in the UK has shown a rapid increase...
Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high-risk UTUC
High-risk upper tract urothelial carcinoma (UTUC) has been associated with poor survival outcomes. The authors evaluated the role of neoadjuvant chemotherapy in high-risk cases prior to radical nephroureterectomy (RNU) in terms of pathological stage of the final surgical specimen. A...Francisco Díaz (1527-1590), forefather of urology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). We often talk about urology being the oldest surgical specialty and discuss the...Prostate cancer in men of African heritage: understanding the risk and prognostic factors
Prostate cancer (PCa) represents a major public health concern and is recognised as one of the most common cancers worldwide, accounting for a significant proportion of cancer-related deaths. It is the second most common malignancy among men globally after lung...
Anti-VEGF and PD-1 combinations in renal cell carcinoma
Over the past decade, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) have been central to treating renal cell carcinoma (RCC), with oncologists refining dosing strategies to balance treatment efficacy with quality of life (QoL). Recently, the introduction of...
Defining adjuvant, consolidative, and salvage treatment after RP
The most common oncologic outcome following radical prostatectomy (RP) for localised prostate cancer is achieving undetectable prostate-specific antigen (PSA) levels (<0.1 ng/ml), indicating an absence of detectable disease. However, the landscape of RP is shifting as active surveillance becomes the...
Are standard repeat biopsies during active surveillance for prostate cancer still necessary?
Active surveillance (AS) has emerged as a key strategy for managing low-risk prostate cancer (PCa), offering an alternative to immediate treatment. Initially, AS relied on prostate specific antigen (PSA) testing, digital rectal examinations (DRE), and systematic biopsies. Early studies using...Blaedderwaerc and other names
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I said I would explore the history of something...
Adjuvant radiotherapy versus wait-and-see after radical prostatectomy
Optimum treatment modalities in prostate cancer continue to evolve, with debates at each stage of the evolution process, from focal therapy to radical treatment. In this randomised study, Wiegel et al. investigated the role of adjuvant radiotherapy following open radical...Prostate Scotland launches new research project into BPE with support from the Grand Lodge of Scotland
Prostate Scotland has launched a new two-year research project into benign prostatic enlargement (BPE), thanks to long-term funding support from The Grand Lodge of Scotland and Scottish Freemasons. The project aims to build a clearer picture of the experiences of...
